QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.004093v1 33/7/1017    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luukkanen, L. Articles by Finel, M. Search for Related Content PubMed PubMed Citation Articles by Luukkanen, L. Articles by Finel, M.

KINETIC CHARACTERIZATION OF THE 1A SUBFAMILY OF RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASES

Division of Pharmaceutical Chemistry (L.L., J.T., R.K.), Viikki Drug Discovery Technology Center (M.K., M.F.), and Division of Pharmaceutical Technology (J.H.), Faculty of Pharmacy, University of Helsinki, Finland

The initial glucuronidation rates were determined for eight recombinant human UDP-glucuronosyltransferases (UGTs) of the 1A subfamily, and the bisubstrate kinetics and inhibition patterns were analyzed. At low substrate concentrations, the reactions followed general ternary complex kinetics, whereas at higher concentrations of both substrates, the reactions were mostly characterized by ternary complex kinetics with substrate inhibition. The glucuronidation of entacapone by UGT1A9 was inhibited by 1-naphthol in a competitive fashion, with respect to entacapone, and an uncompetitive fashion, with respect to UDP-glucuronic acid (UDPGA). Its inhibition by UDP, on the other hand, was noncompetitive with respect to entacapone and competitive with respect to UDPGA. These inhibition patterns are compatible with a compulsory ordered bi bi mechanism in which UDPGA is the first-binding substrate. Despite the identical primary structure of the C-terminal halves of the UGT1A isoforms, there were marked differences in the respective K_m values for UDPGA, ranging from 52 µM for UGT1A6 to 1256 µM for UGT1A8. Relative specificity constants were calculated for the eight UGT1A isoforms with 1-hydroxypyrene, 4-nitrophenol, scopoletin, 4-methylumbelliferone, and entacapone as aglycone substrates. The results demonstrated that seven of the UGT1A isoforms are capable of conjugating phenolic substrates with similar highest k_cat values, and UGT1A4 has a lower relative turnover rate. The highest specificity constants were obtained for 1-hydroxypyrene, even with UGT1A6, which has been regarded as a specific isoform for small planar phenols. A k_cat value of 1.9 s^–1 was calculated for the glucuronidation of scopoletin by purified UGT1A9.

This article has been cited by other articles:

				R. Fujiwara, M. Nakajima, H. Yamanaka, and T. Yokoi Key Amino Acid Residues Responsible for the Differences in Substrate Specificity of Human UDP-Glucuronosyltransferase (UGT)1A9 and UGT1A8 Drug Metab. Dispos., January 1, 2009; 37(1): 41 - 46. [Abstract] [Full Text] [PDF]

				A.-S. Patana, M. Kurkela, M. Finel, and A. Goldman Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases Protein Eng. Des. Sel., September 1, 2008; 21(9): 537 - 543. [Abstract] [Full Text] [PDF]

				Y. Xiong, A.-S. Patana, M. J. Miley, A. K. Zielinska, S. M. Bratton, G. P. Miller, A. Goldman, M. Finel, M. R. Redinbo, and A. Radominska-Pandya The First Aspartic Acid of the DQxD Motif for Human UDP-Glucuronosyltransferase 1A10 Interacts with UDP-Glucuronic Acid during Catalysis Drug Metab. Dispos., March 1, 2008; 36(3): 517 - 522. [Abstract] [Full Text] [PDF]

				R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates Drug Metab. Dispos., February 1, 2008; 36(2): 361 - 367. [Abstract] [Full Text] [PDF]

				A.-S. Patana, M. Kurkela, A. Goldman, and M. Finel The Human UDP-Glucuronosyltransferase: Identification of Key Residues within the Nucleotide-Sugar Binding Site Mol. Pharmacol., September 1, 2007; 72(3): 604 - 611. [Abstract] [Full Text] [PDF]

				T. Sten, S. Qvisen, P. Uutela, L. Luukkanen, R. Kostiainen, and M. Finel Prominent but Reverse Stereoselectivity in Propranolol Glucuronidation by Human UDP-Glucuronosyltransferases 1A9 and 1A10 Drug Metab. Dispos., September 1, 2006; 34(9): 1488 - 1494. [Abstract] [Full Text] [PDF]

				M. Finel, X. Li, D. Gardner-Stephen, S. Bratton, P. I. Mackenzie, and A. Radominska-Pandya Human UDP-Glucuronosyltransferase 1A5: Identification, Expression, and Activity J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1143 - 1149. [Abstract] [Full Text] [PDF]

				D. Zhang, T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION Drug Metab. Dispos., November 1, 2005; 33(11): 1729 - 1739. [Abstract] [Full Text] [PDF]